Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 5Leukemia, Hairy Cell 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vomiting 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1NSCLC 1Myelodysplastic Syndromes 1Mastocytosis, Systemic 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Radiotherapy 4Pemetrexed 4Carboplatin 4pembrolizumab 3osimertinib 3aflutinib 3Radiosurgery 3Drug Therapy 3toripalimab 2Docetaxel 2tislelizumab 1sugemalimab 1lenvatinib 1cemiplimab 1brigatinib 1Vinorelbine 1Tyrosine Kinase Inhibitors 1Surgical Procedures, Operative 1S 1 (combination) 1Platinum Compounds 1Platinum 1Pharmaceutical Preparations 1Paclitaxel 1Neoadjuvant Therapy 1JDQ443 1Immune Checkpoint Inhibitors 1HM781-36B 1Gemcitabine 1Diphenhydramine 1Cryotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC × Diphenhydramine × 1 year × Clear all
NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
120 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡